Melanoma genotypes and phenotypes get personal

[1]  D. Hoon,et al.  Epigenetic biomarkers in skin cancer. , 2014, Cancer letters.

[2]  L. Kwong,et al.  Targeted therapy for melanoma: rational combinatorial approaches , 2014, Oncogene.

[3]  K. Flaherty,et al.  Meeting report: The future of preclinical mouse models in melanoma treatment is now , 2013, Pigment cell & melanoma research.

[4]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  H. Okano,et al.  Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo. , 2013, The Journal of investigative dermatology.

[6]  R. Sullivan,et al.  MAP kinase signaling and inhibition in melanoma , 2013, Oncogene.

[7]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[8]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[9]  D. Fisher,et al.  Teens and Indoor Tanning: A Cancer Prevention Opportunity for Pediatricians , 2013, Pediatrics.

[10]  P. Wesseling,et al.  Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. , 2013, Cancer discovery.

[11]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[12]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[13]  V. Sondak,et al.  Targeted therapy in melanoma. , 2013, Clinics in dermatology.

[14]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[15]  C. Shea,et al.  Melanocytes, melanocyte stem cells, and melanoma stem cells. , 2013, Clinics in dermatology.

[16]  A. Marghoob,et al.  New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. , 2013, Journal of the American Academy of Dermatology.

[17]  F. Menaa.  Latest Approved Therapies for Metastatic Melanoma: What Comes Next? , 2013, Journal of skin cancer.

[18]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[19]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[20]  N. Sebire,et al.  Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS , 2013, The Journal of investigative dermatology.

[21]  M. Washington,et al.  Heparin-Binding Epidermal Growth Factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia , 2013, Oncogene.

[22]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[23]  A. Ribas,et al.  Targeting oncogenic drivers and the immune system in melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. von Deimling,et al.  Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes , 2013, The American journal of surgical pathology.

[25]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[26]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[27]  S. Dalton,et al.  Directed differentiation of human pluripotent cells to neural crest stem cells , 2013, Nature Protocols.

[28]  A. von Deimling,et al.  Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma , 2013, The American journal of surgical pathology.

[29]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[30]  M. Čemažar,et al.  IL-12 based gene therapy in veterinary medicine , 2012, Journal of Translational Medicine.

[31]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[32]  J. Maize,et al.  Molecular biology of melanoma. , 2012, Journal of the American Academy of Dermatology.

[33]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[34]  Jochen K. Lennerz,et al.  A UV-independent pathway to melanoma carcinogenesis in the redhair-fairskin background , 2012, Nature.

[35]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[36]  A. Hauschild,et al.  Progression of cutaneous melanoma: implications for treatment , 2012, Clinical & Experimental Metastasis.

[37]  A. Aplin,et al.  BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma , 2012, Cell Death and Differentiation.

[38]  G. McArthur.  The coming of age of MEK. , 2012, The Lancet. Oncology.

[39]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[40]  J. Kaiser.  Profile: Bert Vogelstein. Cancer genetics with an edge. , 2012, Science.

[41]  L. Ferris,et al.  New diagnostic aids for melanoma. , 2012, Dermatologic clinics.

[42]  H. Kluger,et al.  Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies , 2012, Current Oncology Reports.

[43]  Yuri Nikolsky,et al.  Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue , 2012, Journal of Translational Medicine.

[44]  L. Chin,et al.  Melanoma: from mutations to medicine. , 2012, Genes & development.

[45]  Gema Moreno-Bueno,et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.

[46]  F. Nestle,et al.  Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation , 2012, The Journal of experimental medicine.

[47]  K. Flaherty,et al.  From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.

[48]  G. Merlino,et al.  Shedding light on melanocyte pathobiology in vivo. , 2012, Cancer research.

[49]  Trevor J Pugh,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[50]  D. Morton,et al.  AIM1 and LINE-1 Epigenetic Aberrations In Tumor and Serum Relate to Melanoma Progression and Disease Outcome , 2012, The Journal of investigative dermatology.

[51]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[52]  T. Terzian,et al.  Modelling melanoma in mice , 2011, Pigment cell & melanoma research.

[53]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[54]  J. Chipuk,et al.  Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment , 2011, Front. Oncol..

[55]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[56]  M. Herlyn,et al.  The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression , 2011, Journal of visualized experiments : JoVE.

[57]  B. Bastian,et al.  Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma , 2011, The American journal of surgical pathology.

[58]  M. Hidalgo,et al.  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[59]  S. Wickline,et al.  Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. , 2011, Cancer research.

[60]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[61]  D. Polsky,et al.  Noninvasive genomic detection of melanoma , 2011, The British journal of dermatology.

[62]  J. Tenenbaum,et al.  A Melanoma Molecular Disease Model , 2011, PloS one.

[63]  R. Turner,et al.  Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma , 2011, Epigenetics.

[64]  T. Murohara,et al.  Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF , 2011, Laboratory Investigation.

[65]  K. Hoek,et al.  Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.

[66]  S. Egyházi,et al.  High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. , 2010, The Journal of investigative dermatology.

[67]  S. Woodman,et al.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. , 2010, Biochemical pharmacology.

[68]  L. Ellis,et al.  Finding the tumor copycat: Therapy fails, patients don't , 2010, Nature Medicine.

[69]  V. Sondak,et al.  Melanoma--an unlikely poster child for personalized cancer therapy. , 2010, The New England journal of medicine.

[70]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[71]  P. Cassidy,et al.  The p16INK4A tumor suppressor regulates cellular oxidative stress , 2010, Oncogene.

[72]  M. Kashani-Sabet,et al.  Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. , 2010, Journal of the American Academy of Dermatology.

[73]  Q. Zhan,et al.  The embryonic morphogen, Nodal, is associated with channel‐like structures in human malignant melanoma xenografts , 2010, Journal of cutaneous pathology.

[74]  F. Hodi,et al.  Melanoma from bench to bedside: meeting report from the 6th international melanoma congress , 2010, Pigment cell & melanoma research.

[75]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[76]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[77]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[78]  T. Saida,et al.  Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas , 2009, International journal of cancer.

[79]  R. Kurzrock,et al.  Cancer: the road to Amiens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  E. Simpson,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi , 2008, Nature.

[81]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[82]  M. McMahon,et al.  Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival , 2008, Pigment cell & melanoma research.

[83]  U. Rapp,et al.  Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. , 2008, The Journal of investigative dermatology.

[84]  George Poste,et al.  The "seed and soil" hypothesis revisited. , 2008, The Lancet. Oncology.

[85]  M. Herlyn,et al.  Microenvironmental influences in melanoma progression , 2007, Journal of cellular biochemistry.

[86]  R. Rodenburg,et al.  Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. , 2007, The Journal of clinical investigation.

[87]  Dale L. Greiner,et al.  Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.

[88]  J. Lundeberg,et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.

[89]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Millikan,et al.  The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[91]  M. Hendrix,et al.  Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.

[92]  T. Saida,et al.  Genetic alterations in melanocytic tumors. , 2006, Journal of dermatological science.

[93]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  V. Hearing,et al.  From Melanocytes to Melanoma : The Progression to Malignancy , 2005 .

[95]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[96]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[97]  H. Pehamberger,et al.  Comparative histopathology of grey-horse-melanoma and human malignant melanoma. , 2004, Pigment cell research.

[98]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[99]  R. Sweeney,et al.  Metastatic melanoma in horses. , 2002, Journal of veterinary internal medicine.

[100]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[101]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[102]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[103]  M. Miller,et al.  Retrospective Study of 338 Canine Oral Melanomas with Clinical, Histologic, and Immunohistochemical Review of 129 Cases , 2000, Veterinary pathology.

[104]  S. Wolman.  Applications of fluorescence in situ hybridization techniques in cytopathology , 1997, Cancer.

[105]  D. Elder,et al.  Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. , 1993, The American journal of pathology.

[106]  A. Ben-Ze'ev,et al.  Modulation of the metastatic capability in B16 melanoma by cell shape. , 1983, Science.

[107]  Agnes W. O'Brien.  Seed and Soil , 1905, The Elementary School Teacher.

[108]  Massimo Loda,et al.  Investigative pathology: leading the post-genomic revolution , 2012, Laboratory Investigation.

[109]  M. Herlyn,et al.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. , 2012, Advances in pharmacology.

[110]  P. Hersey,et al.  Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. , 2012, Advances in pharmacology.

[111]  B. Bastian,et al.  KIT as a therapeutic target in melanoma. , 2010, The Journal of investigative dermatology.

[112]  J. Reichrath,et al.  UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. , 2008, Advances in experimental medicine and biology.

[113]  D. Pinkel,et al.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.

[114]  C. Warneke,et al.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[115]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.